Psychosocial and Biological Factors Contributing to Body Weight Gain in Schizophrenia

Vella, SC and Pai, NB (2011) Psychosocial and Biological Factors Contributing to Body Weight Gain in Schizophrenia. [Journal (On-line/Unpaginated)]

Full text available as:

PDF - Published Version
Available under License Creative Commons Attribution No Derivatives.



Overweight and obesity are frequently reported to be a significant issue in schizophrenia resulting in the inherent complications of these disorders. Body weight gain also commonly results from treatment with the most tolerable and efficacious pharmacological treatments, second-generation antipsychotics. However there are numerous other factors that contribute to increased body mass in individuals with schizophrenia prior to the initiation of treatment. With prior research indicating that individuals with schizophrenia have higher rates of overweight and obesity before treatment. Therefore this article provides a review of pertinent issues associated with body weight gain in schizophrenia in an attempt to delineate the impact of both the disease and treatment upon body weight gain. The results of the review indicate that body weight gain in schizophrenia occurs from both psychosocial and biological factors that are further compounded by antipsychotic treatment. The article concludes with recommendations for future research.

Item Type:Journal (On-line/Unpaginated)
Keywords:Body weight gain; Psychosocial factors; Biological factors; Schizophrenia; Overweight; Obesity
Subjects:JOURNALS > Online Journal of Health and Allied Sciences
ID Code:7997
Deposited By: Kakkilaya Bevinje, Dr. Srinivas
Deposited On:09 Nov 2012 17:37
Last Modified:09 Nov 2012 17:37

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

1. Tardieu S, Micallef J, Gentile S, Blin O. Weight gain profiles of new anti-psychotics: public health consequences. Obesity Reviews. 2003;4:129-138. doi:10.1046%2Fj.1467-789X.2003.00105.x

2. Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in patients with schizophrenia: Implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology. 2006;31:2091-2120. doi:10.1038%2Fsj.npp.1301051

3. Holt RIG, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes, Obesity and Metabolism; 2009;11:665-679. doi:10.1111%2Fj.1463-1326.2009.01038.x

4. Thakore JH. Metabolic syndrome and schizophrenia. British Journal of Psychiatry. 2005;186(6):455-456. doi:10.1192%2Fbjp.186.6.455

5. Deng C, Weston-Green K, Huang X. The role of histaminergic H1 and H3 in food intake: A mechanism for atypical antipsychotic-induced weight gain? Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2010;34:1-4. doi:10.1016%2Fj.pnpbp.2009.11.009

6. Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, Hetrick S, Rodriguez-Sanchez JM, Perez-Iglesias R, Vazquez-Barquero JL. Antipsychotic-induced weight gain in chronic and first episode psychotic disorders: A systematic critical reappraisal. CNS Drugs. 2008;22(7):547-562.

7. Levine JA, Schleusner SJ, Jensen MD. Energy expenditure and non-exercise activity. The American Journal of Clinical Nutrition. 2000;72:1451-1454.

8. Devlin MJ, Yanovski SZ, Wilson GT. Obesity: What mental health professionals need to know. American Journal of Psychiatry. 2000;157(6):854-866. doi:10.1176%2Fappi.ajp.157.6.854

9. Kirkbride JB, Barker D, Cowden F, Stamps R, Yang M, Jones PB, Coid JW. Psychoses, ethnicity and socio-economic status. British Journal of Psychiatry. 2008;193:18-24. doi:10.1192%2Fbjp.bp.107.041566

10. Peet M. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices. British Journal of Psychiatry. 2004;184(5):404-408. doi:10.1192%2Fbjp.184.5.404

11. Girgis RR, Javitch JA, Lieberman JA. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signalling pathway. Molecular Psychiatry 2008;13:918-929. doi:10.1038%2Fmp.2008.40

12. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Shetty T, Gangadhar BN. Effects of antipsychotic treatment on Insulin-like Growth Factor-1 and cortisol in schizophrenia: A longitudinal study. Schizophrenia Research. 2010;119:131-137. doi:10.1016%2Fj.schres.2010.01.033

13. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Magadi N, Naveen MD, Thirthall J, Bangalore N, Gangadhar BN, Shetty T. Insulin and insulin-like growth factor-1 abnormalities in anti-psychotic-naive schizophrenia. The American Journal of Psychiatry. 2007;164:1557-1560. doi:10.1176%2Fappi.ajp.2007.07020233

14. Volkow ND, Wang G, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. Trends in Cognitive Sciences. 2011;15(1):37-45. doi:10.1016%2Fj.tics.2010.11.001

15. Volkow ND, Wang G, Fowler JS, Tomasi D, Telang F. Addiction: Beyond dopamine reward circuitry. PNAS September 13, 2011;108(37):15037-15042. doi: 10.1073/pnas.1010654108. Available at

16. Tarricone I, Gozzi BF, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychological Medicine. 2010;40:187-200. doi:10.1017%2FS003329170999040


Repository Staff Only: item control page